No Carolina / NY / Florida
Ph: 561.316.3330

spot_img

Gyros Protein Technologies Introduces Gyrolab Generic Rodent ADA Kit Reagents to Support Preclinical Immunogenicity Assessment

The new Roden ADA Kit expedites bioanalysis by removing the need for assay development and optimization across molecules to provide robust, reproducible, reliable data from nanoliter sample volumes. This is beneficial when ADA assessment is evaluated in preclinical animal models where sample volume may be limited.

AI Model Predicts Breast Cancer Risk Without Racial Bias

Summation

  • “The model is able to translate the full diversity of subtle imaging biomarkers in the mammogram, beyond what the naked eye can see, that can predict a woman's future risk of both DCIS and invasive breast cancer,” Dr.
  • The deep learning model consistently outperformed traditional risk models in predicting a woman's risk of developing DCIS, which is early-stage breast cancer, and invasive breast cancer, which is cancer that has potential to spread.
  • “This is a particularly exciting domain for AI, as it demonstrates the opportunity to apply ‘AI for good'—to reduce well-known racial disparities in risk assessment,” said senior author Constance D.

A deep learning artificial intelligence (AI) model that was developed using only mammogram image biomarkers accurately predicted both ductal carcinoma in situ (DCIS) and invasive carcinoma, according to research being presented today at the annual meeting of the Radiological Society of North America (RSNA). Additionally, the model showed no bias across multiple races.

Traditional breast cancer risk assessment models use information obtained from patient questionnaires, such as medical and reproductive history, to calculate a patient’s future risk of developing breast cancer.

“In the domain of precision medicine, risk-based screening has been elusive because we have not been able to accurately evaluate a woman’s risk of developing breast cancer,” said study lead author Leslie R. Lamb, M.D., M.Sc., a breast radiologist at Massachusetts General Hospital (MGH) in Boston. “Even the best existing traditional risk models do not perform well on the individual level.”

Traditional risk models have also demonstrated poor performance across different patient races, most likely due to the data used to develop the model.

“Traditional models likely have racial biases due to the populations on which they were developed,” Dr. Lamb said. “Several of the commonly used models were developed on predominantly European Caucasian populations.”

According to the American Cancer Society, Black women demonstrate the lowest 5-year relative survival rate for breast cancer among all racial and ethnic groups. This translates to a persistent 6% to 8% disparity in 5-year survival rates between Black and white women across all breast cancer types.

To accurately determine breast cancer risk, foster early detection and improve patient survival rates, it is important that risk models are developed that are applicable across different populations.

A deep learning AI risk assessment model developed using mammographic images alone can outperform traditional risk assessment models in future breast cancer development while also mitigating the racial biases seen in traditional models.

In the first study of its kind, Dr. Lamb and colleagues sought to assess the performance of an image-based deep learning risk assessment model in predicting both future invasive breast cancer and DCIS across multiple races.

The model’s performance was assessed by comparing areas under the receiver operating characteristic curve (AUC) with the DeLong test. The AUC score measures the predictive rate of the model on a scale of from 0 to 1. Multiple prior studies have estimated traditional risk model performance measured by AUC in the range of 0.59-0.62 for white women, with much lower performance in women of other races.

The multisite study included 129,340 routine bilateral screening mammograms performed in 71,479 women between 2009 to 2018 with five-year follow-up data. Patient demographics were obtained from electronic medical records, and instances of cancer were identified from the regional tumor registry.

The racial makeup of the study group included white (106,839 exams), Black (6,154 exams), Asian (6,435 exams), self-reported other races (6,257 exams) and unknown (3,655 exams). The mean age of the women was 59 years old.

The deep learning model consistently outperformed traditional risk models in predicting a woman’s risk of developing DCIS, which is early-stage breast cancer, and invasive breast cancer, which is cancer that has potential to spread.

“The model is able to translate the full diversity of subtle imaging biomarkers in the mammogram, beyond what the naked eye can see, that can predict a woman’s future risk of both DCIS and invasive breast cancer,” Dr. Lamb said. “The deep learning image-only risk model can provide increased access to more accurate, equitable and less costly risk assessment.”

The predictive rate of both DCIS and invasive cancer was 0.71 across all races. The AUC in predicting DCIS was 0.77 in non-white patients and 0.71 in white patients. The AUC in predicting invasive cancer was 0.72 in non-white patients and 0.71 in white patients.

“This is a particularly exciting domain for AI, as it demonstrates the opportunity to apply ‘AI for good’—to reduce well-known racial disparities in risk assessment,” said senior author Constance D. Lehman, M.D., Ph.D., a breast radiologist at MGH. “We are now poised to translate these findings into improved clinical care for our patients.”

Additional co-authors are Sarah F. Mercaldo, Ph.D., and Andrew R. Carney, M.S.

SonoVascular Enters Into Strategic Collaboration with Lantheus Holdings | for Use of Microbubbles in Combination with SonoThrombectomy™ System for Treatment of Venous Thromboembolism

"SonoVascular is honored to have the opportunity to partner with Lantheus, a leader in microbubble development," said Daniel Estay, Founder and Chief Executive Officer of SonoVascular. "Our SonoThrombectomy System, combined with Lantheus' microbubbles, is designed to provide a true, next-generation solution for the treatment of DVT and PE that overcomes the drawbacks associated with catheter-based thrombectomy and thrombolysis devices."

Anaut Announces Japanese Regulatory Approval of AI-Powered Surgical Visualization Tool, Eureka α

Eureka α utilizes state-of-the-art AI to analyze real-time video from laparoscopic and robotic surgery, enhancing surgeons' accuracy by highlighting the dissection planes characterized by connective tissue.

Discover Reeva FT: Revolutionizing Wound Covering for Healthcare Pros

Reeva FT is offered in a variety of sizes: 2x2 cm, 2x3 cm, 4x4 cm, 4x6 cm, 4x8 cm, and 10x15 cm. Reeva FT is confirmed by the FDA Tissue Reference Group to meet the criteria for regulation solely under Section 361 of the PHS Act as defined in 21 CFR Part 1271.
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.
SourceRSNA

By using this website you agree to accept Medical Device News Magazine Privacy Policy